000074975 001__ 74975
000074975 005__ 20200117221636.0
000074975 0247_ $$2doi$$a10.3390/ijms19072081
000074975 0248_ $$2sideral$$a107627
000074975 037__ $$aART-2018-107627
000074975 041__ $$aeng
000074975 100__ $$aCarpéné, C.
000074975 245__ $$aThe dietary antioxidant piceatannol inhibits adipogenesis of human adipose mesenchymal stem cells and limits glucose transport and lipogenic activities in adipocytes
000074975 260__ $$c2018
000074975 5060_ $$aAccess copy available to the general public$$fUnrestricted
000074975 5203_ $$aPhenolic compounds are among the most investigated herbal remedies, as is especially the case for resveratrol. Many reports have shown its anti-aging properties and the ability to reduce obesity and diabetes induced by high-fat diet in mice. However, such beneficial effects hardly translate from animal models to humans. The scientific community has therefore tested whether other plant phenolic compounds may surpass the effects of resveratrol. In this regard, it has been reported that piceatannol reproduces in rodents the anti-obesity actions of its parent polyphenol. However, the capacity of piceatannol to inhibit adipocyte differentiation in humans has not been characterized so far. Here, we investigated whether piceatannol was antiadipogenic and antilipogenic in human preadipocytes. Human mesenchymal stem cells (hMSC), isolated from adipose tissues of lean and obese individuals, were differentiated into mature adipocytes with or without piceatannol, and their functions were explored. Fifty µM of piceatannol deeply limited synthesis/accumulation of lipids in both murine and hMSC-derived adipocytes. Interestingly, this phenomenon occurred irrespective of being added at the earlier or later stages of adipocyte differentiation. Moreover, piceatannol lowered glucose transport into adipocytes and decreased the expression of key elements of the lipogenic pathway (PPAR¿, FAS, and GLUT4). Thus, the confirmation of the antiadipogenic properties of piceatanol in vitro warrants the realization of clinical studies for the application of this compound in the treatment of the metabolic complications associated with obesity.
000074975 536__ $$9info:eu-repo/grantAgreement/ES/FEDER/Una manera de hacer Europa$$9info:eu-repo/grantAgreement/EUR/INTERREG POCTEFA/Refbio-Pyrenees Biomedical Network$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI17-02268
000074975 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000074975 590__ $$a4.183$$b2018
000074975 591__ $$aCHEMISTRY, MULTIDISCIPLINARY$$b45 / 172 = 0.262$$c2018$$dQ2$$eT1
000074975 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b77 / 294 = 0.262$$c2018$$dQ2$$eT1
000074975 592__ $$a1.312$$b2018
000074975 593__ $$aCatalysis$$c2018$$dQ1
000074975 593__ $$aComputer Science Applications$$c2018$$dQ1
000074975 593__ $$aInorganic Chemistry$$c2018$$dQ1
000074975 593__ $$aSpectroscopy$$c2018$$dQ1
000074975 593__ $$aMolecular Biology$$c2018$$dQ1
000074975 593__ $$aOrganic Chemistry$$c2018$$dQ1
000074975 593__ $$aPhysical and Theoretical Chemistry$$c2018$$dQ1
000074975 593__ $$aMedicine (miscellaneous)$$c2018$$dQ1
000074975 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000074975 700__ $$aPejenaute, H.
000074975 700__ $$aDel Moral, R.
000074975 700__ $$aBoulet, N.
000074975 700__ $$aHijona, E.
000074975 700__ $$aAndrade, F.
000074975 700__ $$aVillanueva-Millán, M.J.
000074975 700__ $$aAguirre, L.
000074975 700__ $$0(orcid)0000-0002-8982-3737$$aArbones-Mainar, J.M.
000074975 773__ $$g19, 7 (2018), [14 pp]$$pInt. j. mol. sci.$$tInternational Journal of Molecular Sciences$$x1661-6596
000074975 8564_ $$s306135$$uhttps://zaguan.unizar.es/record/74975/files/texto_completo.pdf$$yVersión publicada
000074975 8564_ $$s109764$$uhttps://zaguan.unizar.es/record/74975/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000074975 909CO $$ooai:zaguan.unizar.es:74975$$particulos$$pdriver
000074975 951__ $$a2020-01-17-22:02:17
000074975 980__ $$aARTICLE